Uk Erectile Dysfunction Market
市场规模（十亿美元）
CAGR :
% 
 Forecast Period |
2024 –2031 |
 Market Size (Base Year) |
USD 260.49 Million |
 Market Size (Forecast Year) |
USD 451.63 Million |
 CAGR |
% |
| Major Markets Players |
>英国勃起功能障碍市场，按产品类型（药品和设备）、类型（继发性勃起功能障碍和原发性勃起功能障碍）、年龄组（40 岁以下、40-60 岁和 60 岁以上）、最终用户（医院、专科诊所、家庭医疗保健、门诊手术中心等）、分销渠道（直接招标、零售药房、网上药房、医院药房等）划分 - 行业趋势和预测到 2031 年。
英国勃起功能障碍市场分析与洞察
男性勃起功能障碍发病率上升、生活方式改变和环境因素影响健康是推动市场需求的一些因素。政府为改善这种状况和福祉而采取的举措进一步推动了市场的增长。
影响市场的主要制约因素是某些产品带来的不良影响。慢性病和生活方式的增加为市场增长提供了机遇。熟练专业人员的缺乏为市场增长带来了挑战。
Data Bridge Market Research 分析称，英国勃起功能障碍市场规模预计将从 2023 年的 2.6049 亿美元增至 2031 年的 4.5163 亿美元，在 2024 年至 2031 年的预测期内，复合年增长率为 7.2%。
|
报告指标 |
细节 |
|
预测期 |
2024 至 2031 年 |
|
基准年 |
2023 |
|
历史岁月 |
2022（可定制为 2016 – 2021） |
|
定量单位 |
收入（百万美元） |
|
涵盖的领域 |
产品类型（药品和设备）、类型（继发性勃起功能障碍和原发性勃起功能障碍）、年龄组（40 岁以下、40-60 岁和 60 岁以上）、最终用户（医院、专科诊所、家庭医疗保健、门诊手术中心等）、分销渠道（直接招标、零售药店、网上药店、医院药店等） |
|
覆盖国家 |
英国 |
|
涵盖的市场参与者 |
Lupin、Teva Pharmaceutical Industries Ltd.、Augusta Medical Systems、Boston Scientific Corporation、Coloplast Corp、Rigicon, Inc.、Pfizer Inc.、Bayer AG、Eli Lily and Company、Viatris Inc.、ZSI、Zephyr Surgical Implants 等 |
市场定义
勃起功能障碍 (ED) 是指无法勃起或保持勃起，无法进行性交。有时也称为“阳痿”，但现在这个术语使用得较少。勃起功能障碍是一个持续存在的问题，可能会导致压力、影响自信心并影响人际关系
勃起功能障碍 (ED) 可因勃起过程的任何阶段出现问题而发生，可能是偶尔发生，也可能频繁发生：
- 偶尔出现勃起功能障碍并不罕见。许多人在压力大的时候或最近营养或生活方式改变后都会出现勃起功能障碍。
- 然而，频繁出现勃起功能障碍可能是健康问题的征兆，需要治疗。这也可能是情绪或人际关系出现问题的征兆，您可能需要找专业人士来处理。
当血液充满两个称为阴茎海绵体的腔室时，您就会勃起。这会导致您的阴茎膨胀和变硬，就像充满水的气球一样。来自大脑和生殖神经的冲动启动了这一过程。任何阻碍这些冲动或限制血液流向阴茎的因素都可能导致 ED。
英国勃起功能障碍市场动态
本节旨在了解市场驱动因素、机遇、限制因素和挑战。下文将详细讨论所有这些内容：
司机
- 慢性病患病率上升
糖尿病会导致全身血管受损，这种情况称为糖尿病血管病变。这种血管损伤会损害包括阴茎在内的各种器官的血流，从而导致勃起功能障碍。随着时间的推移，糖尿病相关血管损伤的累积效应会增加勃起功能障碍 (ED) 发生的可能性和严重程度。糖尿病常常会导致神经病变，这是一种以神经损伤为特征的疾病。周围神经病变会影响大脑和脊髓以外的神经，包括控制勃起和性唤起的神经。因此，糖尿病神经病变会破坏实现和维持勃起的正常神经通路，导致 ED。
克制
- 审批的监管限制
在英国，勃起功能障碍 (ED) 市场的监管限制主要围绕 ED 药物和治疗方法的批准和营销。MHRA（药品和保健产品管理局）是英国监管机构，负责确保药品和医疗器械的安全性、质量和有效性。任何用于治疗 ED 的药物都必须经过 MHRA 的严格评估和批准，然后才能在英国销售和开处方。许多用于治疗 ED 的药物，例如西地那非（伟哥）、他达拉非（希爱力）和伐地那非（艾力达），在英国被归类为 POM（处方药）。这意味着它们只能凭合格的医疗保健专业人员（例如医生或药剂师开具处方）获得。
为了获得监管部门的批准，制药公司必须进行广泛的临床试验，以证明其治疗勃起功能障碍的药物的安全性和有效性。MHRA 会评估这些试验数据，以确定药物的益处是否大于任何潜在风险。
机会
- 处方药及其通用药物的可用性
ED 处方药的供应确保了患者能够获得有效的治疗选择。西地那非（仿制伟哥）、他达拉非（仿制希爱力）和伐地那非（仿制艾力达）等处方药已被证明能够通过改善阴茎血流有效治疗 ED。通过医疗保健提供者随时提供这些药物，ED 患者可以及时寻求治疗，从而提高生活质量和满意度。
治疗勃起功能障碍的仿制药处方药价格通常低于品牌药。价格的提高使更广泛的人群更容易获得治疗，包括那些以前买不起品牌药的人。因此，更多的人可能会寻求治疗勃起功能障碍，从而推动市场需求。
挑战
- 与勃起功能障碍药物相关的各种副作用
治疗勃起功能障碍的药物副作用包括头痛、潮红、头晕、鼻塞和胃肠道不适，这引发了人们对患者安全性和耐受性的担忧。这些不良反应可能会阻止某些人使用治疗勃起功能障碍的药物或导致停止治疗，从而导致市场需求减少和增长放缓。
副作用会影响患者对 ED 药物治疗方案的依从性。如果患者出现令人困扰的副作用，他们可能不太可能遵守规定的用药时间表，甚至可能完全停止治疗。治疗依从性差可能会影响治疗效果并降低 ED 药物的有效性，从而限制受益于治疗的人数，从而阻碍市场增长。
最新动态
- 2023 年 11 月，Rigicon, Inc. 发表了一项综合研究，重点介绍了全球植入的 Rigi10TM 可塑性阴茎假体的安全性结果。这项名为“全球植入的首批 Rigi10 可塑性阴茎假体的安全性结果”的临床研究对 Rigi10 可塑性阴茎假体的安全性进行了全面评估。这项研究强调了该设备作为寻求治疗勃起功能障碍 (ED) 患者的可靠解决方案的地位。这有助于该公司加强其治疗勃起功能障碍的产品组合。
- 2021 年 4 月，根据 NCBI 的数据，Zephyr Surgical Implants 改进了 ZSI 475 的泵缸连接管，开发了额外的加固装置，以增强假体的坚固性。这有助于该公司加强其产品组合。
英国勃起功能障碍市场范围
根据产品、给药途径、剂量、产品类型、购买方式、类型、人群类型、最终用户和分销渠道，英国勃起功能障碍市场可分为 12 个显著细分市场。细分市场之间的增长有助于您分析利基增长领域和进入市场的策略，并确定您的核心应用领域和目标市场的差异。
按产品类型
- 药物
- 设备
按类型
- 继发性勃起功能障碍
- 原发性勃起功能障碍
按年龄组
- 少于 40
- 40-60
- 60 - 以上
按最终用户
- 医院
- 专科诊所
- 家庭医疗保健
- 门诊手术中心
- 其他的
按分销渠道
- 直接招标
- 医院药房
- 零售药店
- 网上药店
- 其他的
英国勃起功能障碍市场份额分析和竞争格局
英国勃起功能障碍市场竞争格局提供了竞争对手的详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、生产基地和设施、公司优势和劣势、产品发布、产品批准、产品宽度和广度、应用主导地位以及产品类型生命线曲线。以上提供的数据点仅与公司对市场的关注有关。
该市场的一些主要市场参与者包括 Lupin、Teva Pharmaceutical Industries Ltd.、Augusta Medical Systems、Boston Scientific Corporation、Coloplast Corp、Rigicon, Inc.、Pfizer Inc.、Bayer AG、Eli Lily and Company、Viatris Inc.、ZSI、Zephyr Surgical Implants 等。
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF U.K. ERECTILE DYSFUNCTION MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET END USER COVERAGE GRID
2.8 PRODUCT LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER'S FIVE FORCES MODEL
4.3 VENDOR SHARE ANALYSIS
4.4 BRAND ANALYSIS
4.4.1 LEADING BRANDS
4.4.2 BRAND POSITIONING
4.4.3 MARKET PENETRATION
4.4.4 COMPETITIVE ANALYSIS
4.5 CONSUMER INSIGHTS
4.5.1 DEMOGRAPHIC INSIGHTS
4.5.2 PSYCHOGRAPHIC PROFILE
4.5.3 CONSUMER PREFERENCES
4.5.4 PURCHASING BEHAVIOUR
4.5.5 FACTORS INFLUENCING BUYING DECISION
4.6 PERFORMANCE ANALYSIS
4.6.1 TREND ANALYSIS
4.7 RETAIL ANALYSIS
5 MARKET OVERVIEW
5.1 DRIVERS
5.1.1 RISING PREVALENCE OF CHRONIC DISEASES
5.1.2 RISING ADOPTION OF SEDENTARY LIFESTYLE AND ASSOCIATED STRESS
5.1.3 RISING PRODUCT LAUNCHES BY MAJOR MARKET PLAYERS
5.1.4 RISING PATIENT AWARENESS REGARDING THE CONDITION AND MEDICATION
5.2 RESTRAINTS
5.2.1 REGULATORY CONSTRAINTS FOR APPROVAL
5.2.2 HIGH COST OF ERECTILE DYSFUNCTION TREATMENT
5.3 OPPORTUNITIES
5.3.1 AVAILABILITY OF PRESCRIPTION MEDICATION AND ITS GENERIC VERSION
5.3.2 RISING TECHNOLOGICAL ADVANCEMENTS
5.3.3 RISING RESEARCH AND DEVELOPMENT ACTIVITIES
5.4 CHALLENGES
5.4.1 VARIOUS SIDE EFFECTS ASSOCIATED WITH ERECTILE DYSFUNCTION DRUGS
5.4.2 LACK OF SKILLED PROFESSIONALS
6 U.K. ERECTILE DYSFUNCTION MARKET, BY PRODUCT TYPE
6.1 OVERVIEW
6.2 DRUGS
6.2.1 ORAL DRUGS
6.2.1.1 BRANDED
6.2.1.1.1 VIAGRA
6.2.1.1.2 CIALIS
6.2.1.1.3 LEVITRA
6.2.1.1.4 AVANAFIL
6.2.1.1.5 OTHERS
6.2.1.2 GENERIC
6.2.2 TOPICAL FORMULATION
6.2.3 PENILE INJECTIONS
6.2.3.1 PAPAVERINE
6.2.3.2 PHENTOLAMINE
6.2.3.3 PROSTAGLANDIN E1 (PGE1)
6.2.4 SUPPOSITORIES
6.3 DEVICES
6.3.1 PENIS PUMPS/VACCUM CONSTRICTION DEVICES
6.3.1.1 HAND-POWERED
6.3.1.2 BATTERY-POWERED PUMP
6.3.2 PENILE IMPLANTS
6.3.2.1 SEMIRIGID/MALLEABLE
6.3.2.2 INFLATABLE
6.3.3 SHOCK WAVE THERAPY
7 U.K. ERECTILE DYSFUNCTION MARKET, BY TYPE
7.1 OVERVIEW
7.2 SECONDARY ERECTILE DYSFUNCTION
7.3 PRIMARY ERECTILE DYSFUNCTION
8 U.K. ERECTILE DYSFUNCTION MARKET, BY AGE GROUP
8.1 OVERVIEW
8.2 LESS THAN 40
8.3 40-60
8.4 60 AND ABOVE
9 U.K. ERECTILE DYSFUNCTION MARKET, BY END USER
9.1 OVERVIEW
9.2 HOSPITALS
9.3 SPECIALTY CLINICS
9.4 HOME HEALTHCARE
9.5 AMBULATORY SURGICAL CENTERS
9.6 OTHERS
10 U.K. ERECTILE DYSFUNCTION MARKET, BY DISTRIBUTION CHANNEL
10.1 OVERVIEW
10.2 DIRECT TENDERS
10.3 HOSPITAL PHARMACY
10.4 RETAIL PHARMACY
10.5 ONLINE PHARMACY
10.6 OTHERS
11 U.K. ERECTILE DYSFUNCTION MARKET, COMPANY LANDSCAPE
11.1 COMPANY SHARE ANALYSIS: GLOBAL
12 SWOT ANALYSIS
13 COMPANY PROFILES
13.1 PFIZER INC.
13.1.1 COMPANY SNAPSHOT
13.1.2 REVENUE ANALYSIS
13.1.3 PRODUCT PORTFOLIO
13.1.4 RECENT DEVELOPMENTS
13.2 LUPIN
13.2.1 COMPANY SNAPSHOT
13.2.2 REVENUE ANALYSIS
13.2.3 PRODUCT PORTFOLIO
13.2.4 RECENT DEVELOPMENTS
13.3 COLOPLAST CORP
13.3.1 COMPANY SNAPSHOT
13.3.2 REVENUE ANALYSIS
13.3.3 PRODUCT PORTFOLIO
13.3.4 RECENT DEVELOPMENTS
13.4 VIATRIS INC.
13.4.1 COMPANY SNAPSHOT
13.4.2 REVENUE ANALYSIS
13.4.3 PRODUCT PORTFOLIO
13.4.4 RECENT DEVELOPMENTS
13.5 TEVA PHARMACEUTICAL INDUSTRIES LTD.
13.5.1 COMPANY SNAPSHOT
13.5.2 REVENUE ANALYSIS
13.5.3 PRODUCT PORTFOLIO
13.5.4 RECENT DEVELOPMENTS
13.6 AUGUSTA MEDICAL SYSTEMS
13.6.1 COMPANY SNAPSHOT
13.6.2 PRODUCT PORTFOLIO
13.6.3 RECENT DEVELOPMENT
13.7 BAYER AG
13.7.1 COMPANY SNAPSHOT
13.7.2 REVENUE ANALYSIS
13.7.3 PRODUCT PORTFOLIO
13.7.4 RECENT DEVELOPMENTS
13.8 BOSTON SCIENTIFIC CORPORATION
13.8.1 COMPANY SNAPSHOT
13.8.2 REVENUE ANALYSIS
13.8.3 PRODUCT PORTFOLIO
13.8.4 RECENT DEVELOPMENTS
13.9 ELI LILY AND COMPANY
13.9.1 COMPANY SNAPSHOT
13.9.2 REVENUE ANALYSIS
13.9.3 PRODUCT PORTFOLIO
13.9.4 RECENT DEVELOPMENTS
13.1 RIGICON, INC.
13.10.1 COMPANY SNAPSHOT
13.10.2 PRODUCT PORTFOLIO
13.10.3 RECENT DEVELOPMENT
13.11 ZEPHYR SURGICAL IMPLANTS.
13.11.1 COMPANY SNAPSHOT
13.11.2 PRODUCT PORTFOLIO
13.11.3 RECENT DEVELOPMENT
14 QUESTIONNAIRE
15 RELATED REPORTS
表格列表
TABLE 1 U.K. ERECTILE DYSFUNCTION MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 2 U.K. DRUGS IN ERECTILE DYSFUNCTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 3 U.K. ORAL DRUGS IN ERECTILE DYSFUNCTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 4 U.K. BRANDED IN ERECTILE DYSFUNCTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 5 U.K. PENILE INJECTIONS IN ERECTILE DYSFUNCTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 6 U.K. DEVICES IN ERECTILE DYSFUNCTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 7 U.K. PENIS PUMPS/VACCUM CONSTRICTION DEVICES IN ERECTILE DYSFUNCTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 8 U.K. PENILE IMPLANTS IN ERECTILE DYSFUNCTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 9 U.K. ERECTILE DYSFUNCTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 10 U.K. ERECTILE DYSFUNCTION MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)
TABLE 11 U.K. ERECTILE DYSFUNCTION MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 12 U.K. ERECTILE DYSFUNCTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
图片列表
FIGURE 1 U.K. ERECTILE DYSFUNCTION MARKET: SEGMENTATION
FIGURE 2 U.K. ERECTILE DYSFUNCTION MARKET: DATA TRIANGULATION
FIGURE 3 U.K. ERECTILE DYSFUNCTION MARKET: DROC ANALYSIS
FIGURE 4 U.K. ERECTILE DYSFUNCTION MARKET: REGIONAL VS COUNTRY MARKET ANALYSIS
FIGURE 5 U.K. ERECTILE DYSFUNCTION MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 U.K. ERECTILE DYSFUNCTION MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 U.K. ERECTILE DYSFUNCTION MARKET: MARKET END USER COVERAGE GRID
FIGURE 8 U.K. ERECTILE DYSFUNCTION MARKET: DBMR MARKET POSITION GRID
FIGURE 9 U.K. ERECTILE DYSFUNCTION MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 U.K. ERECTILE DYSFUNCTION MARKET: SEGMENTATION
FIGURE 11 THE RISING RATES OF CHRONIC DISEASES AMONG MEN IS EXPECTED TO DRIVE THE GROWTH OF THE U.K. ERECTILE DYSFUNCTION MARKET FROM 2024 TO 2031
FIGURE 12 THE DRUGS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE U.K. ERECTILE DYSFUNCTION MARKET IN 2024 AND 2031
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF U.K ERECTILE DYSFUNCTION MARKET
FIGURE 14 U.K. ERECTILE DYSFUNCTION MARKET: BY PRODUCT TYPE, 2022
FIGURE 15 U.K. ERECTILE DYSFUNCTION MARKET: BY PRODUCT TYPE, 2024-2031 (USD MILLION)
FIGURE 16 U.K. ERECTILE DYSFUNCTION MARKET: BY PRODUCT TYPE, CAGR (2024-2031)
FIGURE 17 U.K. ERECTILE DYSFUNCTION MARKET: BY PRODUCT TYPE, LIFELINE CURVE
FIGURE 18 U.K. ERECTILE DYSFUNCTION MARKET: BY TYPE, 2022
FIGURE 19 U.K. ERECTILE DYSFUNCTION MARKET: BY TYPE, 2024-2031 (USD MILLION)
FIGURE 20 U.K. ERECTILE DYSFUNCTION MARKET: BY TYPE, CAGR (2024-2031)
FIGURE 21 U.K. ERECTILE DYSFUNCTION MARKET: BY TYPE, LIFELINE CURVE
FIGURE 22 U.K. ERECTILE DYSFUNCTION MARKET: BY AGE GROUP, 2022
FIGURE 23 U.K. ERECTILE DYSFUNCTION MARKET: BY AGE GROUP, 2024-2031 (USD MILLION)
FIGURE 24 U.K. ERECTILE DYSFUNCTION MARKET: BY AGE GROUP, CAGR (2024-2031)
FIGURE 25 U.K. ERECTILE DYSFUNCTION MARKET: BY AGE GROUP, LIFELINE CURVE
FIGURE 26 U.K. ERECTILE DYSFUNCTION MARKET: BY END USER, 2023
FIGURE 27 U.K. ERECTILE DYSFUNCTION MARKET: BY END USER, 2024-2031 (USD MILLION)
FIGURE 28 U.K. ERECTILE DYSFUNCTION MARKET: BY END USER, CAGR (2024-2031)
FIGURE 29 U.K. ERECTILE DYSFUNCTION MARKET: BY END USER, LIFELINE CURVE
FIGURE 30 U.K. ERECTILE DYSFUNCTION MARKET: BY DISTRIBUTION CHANNEL, 2022
FIGURE 31 U.K. ERECTILE DYSFUNCTION MARKET: BY DISTRIBUTION CHANNEL, 2024-2031 (USD MILLION)
FIGURE 32 U.K. ERECTILE DYSFUNCTION MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2031)
FIGURE 33 U.K. ERECTILE DYSFUNCTION MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 34 U.K. ERECTILE DYSFUNCTION MARKET: COMPANY SHARE 2023 (%)
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
